Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call
March 28, 2023 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4-2022 and year end shareholder update call on Monday,...
Precipio Ships First IV-Cell® Order to Major US Healthcare System
March 21, 2023 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics...
CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:49 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
March 07, 2023 12:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...
ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product”
February 14, 2023 11:44 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) was recognized at ThermoFisher’s National Sales Meeting for the development and...
Precipio Signs Another Major HemeScreen™ Customer
January 11, 2023 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™...
Precipio Signs Additional Major HemeScreen™ Customer
December 06, 2022 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™...
Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference
November 07, 2022 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the...
Precipio Announces Third Quarter Shareholder Update Call
November 02, 2022 17:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2022 shareholder update call on Monday, November 14th...
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™
September 15, 2022 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution...